Media
Intra-Arterial Gemcitabine Showed Promise for Locally Advanced Pancreatic Cancer
August 15, 2023
At the 2023 World Congress on Gastrointestinal Cancers, Michael Pishvaian, MD, PhD, shared data from the first interim analysis of…
RenovoRx Presents Positive Interim Phase III Data in Pancreatic Cancer
July 29, 2023
RenovoRx (NASDAQ:RNXT) presented new positive data on progression-free survival from the pivotal Phase 3 open label TIGeR-PaC study of RenovoGem…
RenovoRx, Imugene Partner to Deliver Oncolytic Virus Therapy
July 24, 2023
RenovoRx, Inc., a clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Ltd., a clinical-stage immuno-oncology company, entered into a…
RenovoRx’s TAMP Platform Will Deliver Imugene’s CF33 Oncolytic Virotherapy in Companies’ Research Collaboration
July 20, 2023
July 20, 2023—RenovoRx, Inc., a Los Altos, California-based clinical-stage biopharmaceutical company developing targeted combination therapies, and Imugene Limited, a clinical-stage…
Survival Benefit Shown With IA Gemcitabine in Patients with Locally Advanced Pancreatic Cancer
July 10, 2023
Prolonged progression-free survival (PFS) has been demonstrated with intra-arterial (IA) administration of gemcitabine (RenovoGem) in patients with locally advanced pancreatic…
Intra-Arterial Gemcitabine Extends PFS in Locally Advanced Pancreatic Cancer
July 5, 2023
Intra-arterial administration of gemcitabine conferred a median PFS benefit of 8 months when compared with standard of care for patients…
Intra-arterial Gemcitabine Improves OS in Locally Advanced Pancreatic Cancer
June 29, 2023
Treatment with intra-arterial (IA) gemcitabine led to an improvement in overall survival (OS) compared with continued treatment with intravenous (IV)…